Enhance your nephrology practice with CME and tools focused on kidney medicine.
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
June 05, 2026
Glasgow
Translating Evidence Into Practice: Patient-Centered, Guideline-Driven Care in ANCA-Associated Vasculitis
June 04, 2026
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
CKD-aP: Beyond the Surface
Leonie Kraft, MD
The Patient-Clinician Connection in Managing CKD-aP
James Burton, DM, FRCP
Lucio Manenti, MD, PhD
Elevating CKD-aP Care: New Frontier
Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities
Improving Sleep and Mental Health in Patients with CKD-aP
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
Emilio Sanchez, MD, PhD
CKD-aP or Something Else? Decoding the Diagnosis
Is CKD-aP Hiding in Your Dialysis Center?
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Javed Butler, MD, MPH, MBA
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Potassium Binders in Practice: Clinical Trial Evidence
Patrick Rossignol, MD, PhD
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Potassium Binders: Safety Comes First!
Treatment Revolution in IgA Nephropathy
Shikha Wadhwani, MD
Dana Rizk, MD
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Incorporating Targeted Therapies in Treatment Planning for AAV
David Jayne, MD
Bernhard Hellmich, MD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.